research Multiple sclerosis: Side effects of interferon beta therapy and their management
The article suggests managing interferon beta therapy side effects in MS with dose adjustments, medications, and patient education.
Search
for
Sort by
Research
30 / 1000+ results 
research Disease modifying agent related skin reactions in multiple sclerosis: prevention, assessment, and management
The article concludes that proper injection techniques and patient education can prevent serious skin reactions from multiple sclerosis medications.
research Multiple sclerosis disease-modifying therapies: adverse effect surveillance and management
The document concludes that managing side effects of MS therapies is crucial for treatment success and patient adherence.
research Transient hair loss during treatment with dimethyl-fumarate for multiple sclerosis
Dimethyl-fumarate may cause temporary hair loss.
research Alopecia Universalis Occurring after Alemtuzumab Treatment for Multiple Sclerosis. A Two-Year Follow-Up of Two Patients
Two patients developed complete hair loss after Alemtuzumab treatment for MS, with no regrowth after two years.
research Hair Cortisol as a Biomarker of Chronic Stress in Community-Dwelling Adults With Longstanding Multiple Sclerosis
Hair cortisol levels don't reliably indicate chronic stress in people with multiple sclerosis.
research Alopecia Associated to the Use of Disease-Modifying Therapies for Multiple Sclerosis: A Scoping Review Protocol
Some treatments for multiple sclerosis can cause hair loss.
research Skin Complications Associated with Interferon-β Treatment in Patients with Multiple Sclerosis, Tehran in 2021 - 2
Interferon beta treatment in MS patients can cause skin reactions and increased hair loss.
research BH14 Multiple sclerosis and alopecia areata: drug-induced alopecia areata or coexisting autoimmune phenomena?
Some multiple sclerosis treatments may trigger hair loss conditions like alopecia areata.
research Hair loss due to treatment of multiple sclerosis
Hair loss from multiple sclerosis treatments is usually temporary.
research Pain in Multiple Sclerosis: Understanding Pathophysiology, Diagnosis, and Management Through Clinical Vignettes
Effective pain management in multiple sclerosis requires individualized treatment strategies.
research Teriflunomide and Its Mechanism of Action in Multiple Sclerosis
Teriflunomide helps reduce multiple sclerosis symptoms and is safe for most patients.
research Disease-Modifying Therapy in Multiple Sclerosis: Strategies For Optimizing Management
A comprehensive approach to educating patients and managing side effects is crucial for improving adherence to multiple sclerosis treatments and patient quality of life.
research Teriflunomide in multiple sclerosis: an update
Teriflunomide effectively reduces relapses and disability in MS and has a manageable safety profile.
research Real-World Observational Evaluation of Hair Thinning in Patients with Multiple Sclerosis Receiving Teriflunomide: Is It an Issue in Clinical Practice?
Hair thinning is a common but generally mild and reversible side effect of teriflunomide in multiple sclerosis patients.
research The Shifting Landscape of Disease-Modifying Therapies for Relapsing Multiple Sclerosis
New treatments for relapsing multiple sclerosis are more effective and convenient but have higher risks of serious side effects.
research Alopecia Universalis in a Multiple Sclerosis Patient After Switching From Rituximab to Ocrelizumab: A Case Report
Ocrelizumab may cause total body hair loss in some patients.
research Role of isoflavones in multiple sclerosis
Isoflavones from soy may help manage multiple sclerosis symptoms, but more research is needed.
research Skin Lesions in a Daclizumab-treated Patient with Multiple Sclerosis
A patient with multiple sclerosis developed skin reactions after Daclizumab treatment, requiring more data on the drug's effects.
research Teriflunomide (Aubagio®) for the treatment of multiple sclerosis
Teriflunomide is an effective and generally safe oral treatment for relapsing MS, reducing relapses and slowing disability progression.
research Teriflunomide: a novel oral treatment for relapsing multiple sclerosis
Teriflunomide is an effective and safe first-line oral treatment for relapsing multiple sclerosis.
research Does Post-Void Residual Volume Predict Worsening Urological Symptoms in Patients with Multiple Sclerosis?
Post-void residual volume does not predict worsening urological symptoms in multiple sclerosis patients.
research Erosive pustular dermatosis of the scalp and multiple sclerosis: just a coincidence?
EPDS and MS might share an immune-related cause.
research Post-marketing safety profile of cladribine in multiple sclerosis: a disproportionality analysis based on the FDA adverse event reporting system
Cladribine has known risks and potential new safety concerns, requiring careful monitoring.
research BH25 Alopecia in a patient undergoing multiple treatments for multiple sclerosis: a rare presentation and case review
MS treatments can cause significant hair loss, affecting mental health.
research Delayed Onset of Alopecia Areata in a Patient on Ocrelizumab for Multiple Sclerosis: A Case Report
Ocrelizumab may cause delayed hair loss in some patients.
research 3162 Alopecia universalis after alemtuzumab in multiple sclerosis - a nine year follow up and review of literature
Alopecia universalis from alemtuzumab in multiple sclerosis can be reversed with specific treatments.
research Alemtuzumab-Induced Secondary Autoimmune Skin Disorders as Side Effects of Multiple Sclerosis Therapy: Problem That Can Be Influenced or Fate? A Narrative Overview of The Literature A Neuroprotective Role of Vitamin D?
Taking vitamin D might improve life for MS patients and reduce skin side effects from alemtuzumab treatment.
research Teriflunomide: A Once-daily Oral Medication for the Treatment of Relapsing Forms of Multiple Sclerosis
Teriflunomide effectively reduces relapse rates and disease progression in multiple sclerosis but is not safe for use during pregnancy.
research Teriflunomide in Patients with Relapsing–Remitting Forms of Multiple Sclerosis
Teriflunomide is effective and generally safe for treating relapsing-remitting multiple sclerosis.